Will Kythera Biopharma's ATX 101 be the Next Botox?
By Catherine Shaffer
Wednesday, September 1, 2010
Now that Kythera Biopharmaceuticals Inc. has granted rights for ATX 101 to Intendis, a Bayer HealthCare company, in a deal potentially worth $373 million, the landscape for fat reduction drugs is expanding beyond therapeutic obesity indications and into the lucrative aesthetics market. Body shaping technologies are one of the fastest-growing sectors of that rapidly expanding market. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.